San Diego, CA – July 30, 2015 – As Illinois implements the state’s accessibility to medical cannabis, many patients, healthcare and legal professionals exchanged knowledge and resources at the 2nd annual My Compassion Chicago Cannabis Conference at Navy Pier July 23-25. There, CanChew®, the first patented cannabis chewing gum, was sampled by show goers. CanChew® also captured the attention of both mainstream and industry news reporters in features including: ABC, NBC, CBS, Yahoo News, Telemundo, WGN, Marijuana Investor News and more.
“Consumers from coast-to-coast converged on My Compassion’s Chicago Cannabis Conference, an important conference that puts the needs of prospective and current medical marijuana patients first,” stated Stuart W. Titus, PhD and CEO of Medical Marijuana, Inc. “There, many medical professionals shared their bodies of research and valuable knowledge on the evolution of the cannabis industry and offered timelines on cannabis innovations. As a result, we sincerely appreciate the receptivity of the public and news media on sharing knowledge of CanChew® Gum’s immediate availability in all 50 states.”
CanChew® is a unique, patented, award-winning cannabinoid release chewing gum that is distinctly different than any other brand of gum on the market today. Features listed on the CanChew® website include:
An industry leader and innovator, CanChew®, was featured in Healthy Living Magazine’s December issue and also recognized by the HealthyLivinGFoundation and honored with its Triple Leaf Award. CanChew® has been seen in and on:
For more information on CanChew® visit www.CanChewGum.com.
AXIM Biotechnologies, Inc. (OTC: AXIM) is the exclusive license recipient to the world’s first patented cannabinoid release gum. Dr. George E. Anastassov was a conference presenter on cannabinoid delivery methods at the Chicago Cannabis Conference. For more information, visit www.AXIMBiotech.com.
About Medical Marijuana Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For more information, please visit the company's website at: www.MedicalMarijuanaInc.com
About CanChew Biotechnologies, LLC
CanChew Biotechnologies focuses on the treatment of pain and other medical disorders with the application of cannabinoid medical products as well as food and nutraceutical products for general well-being.
The company is focused on the R&D and execution of their clinical development plan and potential out-licensing of their technology. Clinical development focuses on the R&D of the formulation, production and the development of chewing gum-based products for the treatment of conditions like pain, nausea and vomiting, anorexia, spasticity and various other medical issues. For more information on the company, visit CanChewGum.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.